hMaxi-K gene therapy - Urovant Sciences

Drug Profile

hMaxi-K gene therapy - Urovant Sciences

Alternative Names: hMaxi-K - Ion Channel Innovations

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ion Channel Innovations LLC
  • Developer Ion Channel Innovations
  • Class Erectile dysfunction therapies; Gene therapies; Urologics
  • Mechanism of Action Calcium-activated potassium channel openers; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Overactive bladder
  • No development reported Erectile dysfunction

Most Recent Events

  • 31 Aug 2018 Discontinued - Phase-I for Erectile dysfunction in USA (Intracavernous)
  • 28 Aug 2018 hMaxi-K gene therapy licensed to Urovant Sciences worldwide for the treatment of Overactive bladder (Second-line therapy or greater)
  • 28 Aug 2018 No development reported - Phase-II for Erectile dysfunction in Kuwait (Intracavernous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top